The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir/grazoprevir regimens in the United States - Elbasha, E. H.; Robertson, M. N.; Nwankwo, C. (Alimentary pharmacology & therapeutics, 2017)
Keywords: Administration, Oral; Amides; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Benzofurans - administration & dosage; Benzofurans - adverse effects; Carbamates; Chronic infection; Cirrhosis; Clinical trials; Cost analysis; Cost-Benefit Analysis; Cyclopropanes; Drug Resistance, Viral - genetics; Drug Therapy, Combination; Elbasvir plus Grazoprevir for HCV; Genotype; Hepacivirus - genetics; Hepatitis C, Chronic - diagnosis; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - economics; Hepatitis C, Chronic - virology; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Liver cirrhosis; Liver Cirrhosis - drug therapy; Liver Cirrhosis - virology; Liver diseases; Original; Polymorphism, Genetic; Predictive Value of Tests; Quinoxalines - administration & dosage; Quinoxalines - adverse effects; Ribavirin; Ritonavir; Sulfonamides; United States; Viral Nonstructural Proteins - genetics; Virology - economics; Virology - methods; United States